Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 3

Results For "CDMO"

373 News Found

Lupin appoints Abdelaziz Toumi as CEO of its API CDMO subsidiary
People | June 17, 2024

Lupin appoints Abdelaziz Toumi as CEO of its API CDMO subsidiary

Abdel has held leadership positions at Bayer, Merck, Catalent, Lonza, and KBI Biopharma,


Suven to acquire a majority stake in CDMO player ‘Sapala Organics’
News | June 14, 2024

Suven to acquire a majority stake in CDMO player ‘Sapala Organics’

Sapala has a strong customer base including innovator Pharma, CDMOs & diagnostic companies


Grace expands CDMO capacity by 25% of South Haven facility in Michigan
News | March 19, 2024

Grace expands CDMO capacity by 25% of South Haven facility in Michigan

Additional capacity broadens Grace’s fine chemical capabilities for API production


Bajaj Healthcare enters into definitive CDMO Agreement for 15 APIs with UK/EU customers
News | February 29, 2024

Bajaj Healthcare enters into definitive CDMO Agreement for 15 APIs with UK/EU customers

BHL will undertake the development and supply of these molecules


Glenmark Life Sciences inks CDMO supply deal with a Japanese pharma innovator
News | January 19, 2024

Glenmark Life Sciences inks CDMO supply deal with a Japanese pharma innovator

Glenmark Life Sciences will manufacture API in the therapeutic area of urinary anti-spasmodic, to supply to the global innovator


AGC invests US$ 348 million to expand its biopharmaceutical CDMO capability
News | December 21, 2023

AGC invests US$ 348 million to expand its biopharmaceutical CDMO capability

Development services for gene and cell therapies is planned to begin first in 2025


Porton Advanced and Yinjia Biosciences partner to enhance CDMO technology platform
Biotech | February 27, 2023

Porton Advanced and Yinjia Biosciences partner to enhance CDMO technology platform

Yinjia Biosciences will provide Porton Advanced with high-quality core protein raw materials and testing reagent products for quality control and evaluation systems.


Stelis Biopharma’s CDMO partner receives approval for key ANDA from the USFDA
Drug Approval | December 29, 2022

Stelis Biopharma’s CDMO partner receives approval for key ANDA from the USFDA

The current approval is first of the many fillings made by the company's CDMO partners from the flagship facility in Bangalore